Equillium | Investor Presentation Deck

The slide highlights the commonality of the γC receptor subunit across different cytokine receptors, positioning it as a therapeutic target.present_solution

Open slide detail

The slide uses a process flow diagram to explain the scientific methodology behind the company's proprietary therapeutic platform.present_solution

Open slide detail

The slide uses a biological process diagram to illustrate the mechanism and a bar chart to demonstrate selective inhibition.present_solution

Open slide detail

The slide uses a visual comparison framework to contrast three different drug mechanisms.present_solution

Open slide detail

This is a section divider or introductory slide for the product solution.present_solution

Open slide detail

The slide uses a four-column structure to explain the drug's mechanism, structure, preclinical results, and clinical status.present_solution

Open slide detail

The slide uses a structured comparison of four distinct disease areas to justify the market potential of the EQ101 franchise.size_opportunity

Open slide detailBeat · Market Size

The slide uses western blot data to demonstrate the mechanism of action difference between the competitor (Ruxolitinib) and the company's drug (EQ101).present_solution

Open slide detail

Includes clinical trial data and visual evidence of skin improvement.show_traction

Open slide detailBeat · Traction

show_traction

Open slide detailBeat · Traction

The diagram uses a circular flow/flywheel-like representation to show the disease cycle.present_solution

Open slide detail

Includes visual longitudinal study (Day 0, 14, 21) and a bar chart comparing PBS, Ruxolitinib, and EQ101.show_traction

Open slide detail

Data shows higher response rates for 4-mg dose and correlation between baseline severity and treatment efficacy.analyze_data

Open slide detail

The slide uses a combination of qualitative physician sentiment and quantitative survey data to frame the problem of safety in current standard-of-care treatmenframe_problem

Open slide detailLoop · Cost Of Inaction

Includes definition of SALT score in footer.plan_implementation

Open slide detail

transition

Open slide detail

The slide uses a four-column process flow to explain the biological rationale, mechanism, preclinical validation, and development status.present_solution

Open slide detail

The slide uses scientific citations to validate the mechanism of action (IL-21/IL-15) upstream of current therapies.size_opportunity

Open slide detail

Uses a clear contrast between patient count and available treatments to frame the market opportunity.frame_problem

Open slide detail

The slide uses a circular process diagram to illustrate the pathology of celiac disease and provides a stack of academic paper headers as evidence.establish_context

Open slide detail

The diagram shows a circular process where inhibitors block IL-15 and IL-21 to prevent damage to gut epithelium.present_solution

Open slide detail

The slide uses a process-like flow to highlight 'reduce inflammation' as the key target, supported by logos of major pharma companies.present_solution

Open slide detail

The table categorizes competitors by mechanism (Gluten Modification, Barrier Function, Immune Tolerance, Reduce Inflammation) and lists drug names, targets, andcompare_peers

Open slide detail

transition

Open slide detail

The slide uses a grid of headshots for the team and a logo grid for their collective industry experience.other

Open slide detailBeat · Team

The slide uses a timeline-based bar chart to represent the duration of IP protection and exclusivity for various therapeutic assets.analyze_data

Open slide detail

summarize

Open slide detail

The slide combines clinical development timelines with financial runway projections.plan_implementation

Open slide detailLoop · Why Now

state_next_steps

Open slide detail